SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?


To: software salesperson who wrote (1659)6/30/2003 7:15:00 PM
From: Icebrg  Respond to of 3044
 
>>(iii) is the royalty rate around 25% ? - - no direct answer>>

If I heard him correctly, he indicated that there would not be a major difference in profitability between running in Europe royalty-based or in co-promotion mode. This should indicate that the royalty percentage is quite high.

The reason they wanted the co-promotion opportunity is that it will enable them to start building their own European sales force. (He might not be fully aware of the fact that Europe is not one single state, but a fairly large number of them and that he will need one sales force in each country and in some countries more than one).

Erik



To: software salesperson who wrote (1659)6/30/2003 7:24:45 PM
From: PCSS  Read Replies (1) | Respond to of 3044
 
if I hear you correctly (?)

the mkt is overreacting negatively to what should/could/is positive news ---

is this a buying opportunity ?



To: software salesperson who wrote (1659)6/30/2003 7:41:17 PM
From: Icebrg  Read Replies (1) | Respond to of 3044
 
>>(ii) will profitability objectives be hit each year in 2003, 4, 5 , 6, or in toto? - - levin emphasized each individual year

(vii) could 1st milestone be paid in 2003?- - no direct answer>>

Looking at the quarterly figures for the last 5 quarters it is pretty obvious, that if Millennium is to hit its
300 mUSD NOL-target, they will need to bring in those 125 mUSD already this year.



Q1_03 Q4_02 Q3_02 Q2_02 Q1_02


Revenue 81,7 96,8 95,8 91,9 68,6
Other revenue
Total revenue 81,7 96,8 95,8 91,9 68,6

Cost of Revenue -18,7 -18,9 -18,8 -17,8 -7,7
Gross Profit 63,0 77,9 77,0 74,1 60,9

S,G & A -35,4 -38,3 -37,4 -40,1 -37,2
R&D -126,8 -146,9 -140,5 -122,4 -101,3
Depr. /Amort. -9,7 -9,8 -9,8 -9,8 -5,5
Other op. Exp. -28,2 -3,0 -54,0 0,0
Total Op. Exp. -200,1 -198,0 -187,7 -226,3 -144,0

Operating Income -137,1 -120,1 -110,7 -152,2 -83,1

Interest, expense -10,4 -6,1 -10,4 -14,7 -6,8
Interest, income 9,6 15,0 21,7 19,2 28,2
Sales, fixed assets 31,5 0,5 40,0
Other, net
Total Non-operating -0,8 40,4 11,8 44,5 21,4

Net inc. bef. Tax -137,9 -79,7 -98,9 -107,7 -61,7


The above table is a result from preliminary work in the BioMaven 100 group.
We could need a couple more volunteers, who help us to pull together some financial data.
You would be responsible to follow up the results from some 5-10 different companies.

Preferably you should be able to run Groove on your computer. But email might do if you are on a slow connection.

For some further details, please see

Message 19050186

and

Message 19052895

Erik